SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a significant deal with OpenAI, where AMD will become a core compute partner, potentially challenging NVIDIA's dominance in the AI chip market. The community is discussing the implications of OpenAI taking a stake in AMD and the potential for AMD to reach new price targets. This news is driving bullish sentiment and increased trading volume for AMD.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences Inc ($SPRB) is trending due to a significant surge following the FDA's Breakthrough Therapy Designation for its drug targeting Sanfilippo Syndrome Type B, a rare disease. The community is discussing the potential for continued upward momentum, with some comparing it to other high-flying stocks, while others caution about a potential pullback or offering. The stock's low float and the potential for a buyout are also being highlighted as contributing factors to the intense interest.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

SLDP is trending due to positive sentiment surrounding solid-state battery technology and its potential applications, with community members highlighting partnerships, production milestones, and analyst ratings. Conversations suggest anticipation for news and potential short squeezes, with some speculating on the impact of solid-state batteries on electric vehicle performance. Discussions also include comparisons with competitors and varying views on market manipulation.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company ($ABAT) is trending as investors express bullish sentiment, anticipating a potential move towards $7 or $10. Community members highlight the stock's chart, recent volume, and the potential for significant gains, with some pointing to large call option purchases as a positive signal. Speculation around upcoming catalysts, such as the PFS, and potential government interest are also fueling discussions.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to reports of an SEC probe into its data collection practices, sparking debate about potential regulatory impacts. While some investors view the dip as a buying opportunity, citing strong fundamentals and analyst support, others express concern over the company's valuation and potential downside risks. The community is actively discussing the legitimacy and potential impact of the probe, with some dismissing it as a short-selling tactic.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies Corp is trending as discussions revolve around its potential in the quantum computing and cybersecurity space, especially following its NASDAQ listing. Community members are weighing its valuation against competitors and analyzing its recent partnership in South Korea, along with potential revenue streams. Some express concerns about possible dilution, while others remain bullish, citing the company's technology and growth prospects.

Society Pass, Inc. engages in the operation and acquisition of fintech and e-commerce platforms and mobile applications. It operates through the following segments: Online Food and Beverage (F&B) and Groceries Deliveries, Digital Marketing, Online Ticketing and Reservation, e-Commerce, Telecommunication Reseller, and Merchant Point of Sale (POS). The Online F&B and Groceries Deliveries segment includes the operation of Handycart, Mangan, and Pushkart brands. The Digital Marketing segment involves the engagement with creators and management of platforms. The Online Ticketing and Reservation segment focuses on the sale of domestic and overseas air ticket and global hotel reservations. The e-Commerce segment refers to the operation of an online lifestyle platform under the brand name Leflair. The Telecommunication Reseller segment consists of sales of local mobile phone plans and global internet data provider plans. The Merchant POS segment covers the sale of hardware and software. The company was founded by Luan Thuc Nguyen on June 22, 2018 and is headquartered in Carson City, NV.

Society Pass Inc

SOPA is trending as traders discuss its potential for a significant run, drawing comparisons to other recent high-momentum stocks. The community is focused on technical analysis, identifying key entry points and potential price targets. Some investors are highlighting the company's valuation and upcoming IPOs as reasons for optimism.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics ($SERV) is trending as the community discusses its potential in the autonomous delivery space, fueled by expansion news and bullish technical indicators. Conversations revolve around a possible run to higher price levels, with some traders eyeing the stock's chart and unusual options activity as positive signals. The broader robotics sector and potential catalysts, such as partnerships and technological advancements, are also contributing to the increased interest.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending as the community discusses its potential in the quantum computing sector, particularly its post-quantum cryptography and upcoming chip launch. Investors are weighing the potential for a short squeeze amid high short interest and debate the impact of recent warrant exercises and dilution concerns. Bullish sentiment is fueled by upcoming catalysts and the company's strategic partnerships.

Bitcoin SV (BSV) emerged following a hard fork of the Bitcoin Cash (BCH) blockchain in 2018, which had in turn forked from the BTC blockchain a year earlier. The goal of Bitcoin SV is to fulfil the original vision of the Bitcoin protocol and design as described in Satoshi Nakamoto’s white paper, early Bitcoin client software and known Satoshi writings. BSV aims to offer scalability and stability in line with the original description of Bitcoin as a peer-to-peer electronic cash system, as well as deliver a distributed data network that can support enterprise-level advanced blockchain applications. To this end, it has removed artificial block size limits and re-enabled Script commands and other technical capabilities which had been historically disabled or restricted by the protocol developers of the BTC blockchain. This allows the network to process tens of thousands of transactions per second while maintaining extremely low transaction fees for micropayments, in addition to offering advanced capabilities such as tokens, smart contracts, computation and other data use cases. The BSV network is unique in its capacity for unbounded on-chain scaling while also being more aligned with the original design of Bitcoin than any other blockchain.

Bitcoin SV

Bitcoin SV is trending as the community discusses its underlying technology, potential scalability with Teranode, and Craig Wright's ongoing trial, with some speculating about a market impact regardless of the outcome. Bullish community members highlight BSV's transaction capabilities and potential for real-world applications, while others remain skeptical, pointing to its controversial history and delisting from major exchanges. The discussion also includes comparisons to Bitcoin and other cryptocurrencies, focusing on BSV's unique technological approach and potential role in the broader crypto ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Crinetics Pharmaceuticals picked up on Thursday after the U.S. Food and Drug Administration approved its lead therapy Palsonify (paltusotine) for adults with acromegaly.<a href="https://stocktwits.com/symbol/CRNX">Crinetics’ stock</a> closed Thursday up 2.02% at $35.89 and added another 0.8% in after-hours trading.The once-daily oral treatment is the first of its kind to be cleared in the U.S. for patients who do not respond to surgery or are unable to undergo surgery. The FDA decision was supported by two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, in which Palsonify was well-tolerated, provided rapid and durable biochemical control, and reduced symptom burden. Patients reported improvements in headaches, fatigue, joint pain and swelling.Crinetics released&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">long-term data in July</a> from the same studies, showing that patients who switched from monthly injections to Palsonify were able to maintain steady hormone levels for nearly two years.&nbsp;Symptom flares fell significantly, from more than 30% of days on injectable therapies to just 6.2% on stable Palsonify dosing.&nbsp;CEO Scott Struthers called the FDA approval a “new era” for patients and the company, marking the first product launch from its pipeline of small-molecule drugs. The company said Palsonify will be available in the U.S. in early October, supported by a patient services program called CrinetiCARE.Paltusotine is also being evaluated for the treatment of carcinoid syndrome in the pivotal Phase 3 CAREFNDR trial, with global enrollment expected throughout 2025.On Stocktwits, retail sentiment for Crinetics was ‘extremely bullish’ amid a 410% surge in 24-hour message volume, placing it among the top three trending equities on the platform.&nbsp;Users expressed relief after a discussion clarified that while Crinetics sources some ingredients from Europe and previously India, its final tablets are manufactured in the United States, reducing tariff concerns.<stembedurl>https://stocktwits.com/Market_Luther_Kang/message/630073335</stembedurl>Another user remarked that the overwhelmingly positive news, combined with a temporary trading halt, suggested a significant price increase for Crinetics stock could be expected.<stembedurl>https://stocktwits.com/hobbytrader2/message/630067465</stembedurl>Crinetics Pharmaceuticals’ stock has declined 29.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move

The company plans to launch in the U.S. in early October, with a European launch expected in 2026.

Equity

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years.&nbsp;Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks.&nbsp;Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly.&nbsp;Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly.&nbsp;The EMA had previously granted the drug Orphan Drug Designation in February.&nbsp;On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.Crinetics’ stock has declined 38.1% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trumps-35-tariff-threat-ripples-through-walmart-s-bangladesh-supply-chain-report/ch8B1KwR5Np">Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Crinetics Pharmaceuticals' (CRNX) Palsonify (paltusotine) showed sustained biochemical control and symptom relief across two Phase 3 studies. (Photo credit: Getty Images)

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years. 

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Futures Drop On DOJ's Google Crackdown, China Plunge

Futures Drop On DOJ's Google Crackdown, China Plunge

 US equity futures are lower on news that the DOJ is considering a breakup of Alphabet's Google search engine, in what would be a...

Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification

Crinetics Pharmaceuticals (CRNX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan W...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals

Latest Ratings for CRNX
 DateFirmActionFromTo Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2021HC Wainwright...

17 Analysts Have This To Say About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$41.68
Prev Close	$40.86
Open	$41.03
Dividend Yield	0.00%
50-Day Moving Average	$33.10
Beta	1.16
Avg. Volume	1.96M
PE Ratio	-10.13

52-Week High	$62.53
52-Week Low	$24.10
Market Capitalization	$3.93B
EPS (Annual)	-$3.69
Price to Book	3.35
Revenue Per Employee	$2,377.57
Enterprise Value/EBITDA	N/A

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRNX News

CRNX Crinetics Pharmaceuticals Inc